Cargando…

MAF1 is a predictive biomarker in HER2 positive breast cancer

RNA polymerase III transcription is pivotal in regulating cellular growth and frequently deregulated in various cancers. MAF1 negatively regulates RNA polymerase III transcription. Currently, it is unclear if MAF1 is universally deregulated in human cancers. Recently, MAF1 expression has been demons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabarcas-Petroski, Stephanie, Olshefsky, Gabriella, Schramm, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558074/ https://www.ncbi.nlm.nih.gov/pubmed/37801436 http://dx.doi.org/10.1371/journal.pone.0291549

Ejemplares similares

BDP1 as a biomarker in serous ovarian cancer
por: Cabarcas‐Petroski, Stephanie, et al.
Publicado: (2022)

BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer
por: Cabarcas-Petroski, Stephanie, et al.
Publicado: (2022)

A meta-analysis of BRF2 as a prognostic biomarker in invasive breast carcinoma
por: Cabarcas-Petroski, Stephanie, et al.
Publicado: (2020)

Human Maf1 negatively regulates RNA Polymerase III transcription via the TFIIB family members Brf1 and Brf2
por: Rollins, Janet, et al.
Publicado: (2007)

Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein
por: Koo, Jana, et al.
Publicado: (2015)

Gene Expression and DNA Methylation in Human Papillomavirus Positive and Negative Head and Neck Squamous Cell Carcinomas
por: Hinić, Snežana, et al.
Publicado: (2022)

RNA polymerase III transcription in cancer: the BRF2 connection
por: Cabarcas, Stephanie, et al.
Publicado: (2011)

Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells
por: Cabarcas, Stephanie, et al.
Publicado: (2008)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

STARD3: A New Biomarker in HER2-Positive Breast Cancer
por: Lodi, Massimo, et al.
Publicado: (2023)

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
por: Pavlovic, Milica, et al.
Publicado: (2015)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
por: Pobiruchin, Monika, et al.
Publicado: (2016)

Loss of MafA and MafB expression promotes islet inflammation
por: Singh, Tania, et al.
Publicado: (2019)

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
por: You, Ji Young, et al.
Publicado: (2023)

Identification of new miRNA biomarkers associated with HER2-positive breast cancers
por: Tashkandi, Hossam, et al.
Publicado: (2015)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2019)

The role and regulation of Maf proteins in cancer
por: Deng, Yalan, et al.
Publicado: (2023)

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
por: Liu, Yi, et al.
Publicado: (2013)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2020)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population
por: Grela-Wojewoda, Aleksandra, et al.
Publicado: (2022)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

Targeted therapy for HER2 positive breast cancer
por: Incorvati, Jason A, et al.
Publicado: (2013)

Educational Case: HER-2 Positive Breast Cancer
por: Jennings, Julia, et al.
Publicado: (2021)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023)

Circulating metabolites serve as diagnostic biomarkers for HER2‐positive breast cancer and have predictive value for trastuzumab therapy outcomes
por: Mao, Changfei, et al.
Publicado: (2022)

MafB Maintains β-Cell Identity under MafA-Deficient Conditions
por: Deng, Zhaobin, et al.
Publicado: (2022)

HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Lillemoe, Tamera J., et al.
Publicado: (2021)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Nitrilases NIT1/2/3 Positively Regulate Flowering by Inhibiting MAF4 Expression in Arabidopsis
por: Yang, Shuang, et al.
Publicado: (2022)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
por: Guiu, S., et al.
Publicado: (2013)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i5lusifimct8n24r5erg36o667